Summary

Therapeutic Plasma Exchange Market – Scope of Report
TMR’s report on the global therapeutic plasma exchange market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global therapeutic plasma exchange market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global therapeutic plasma exchange market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the therapeutic plasma exchange market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global therapeutic plasma exchange market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global therapeutic plasma exchange market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global therapeutic plasma exchange market.

The report delves into the competitive landscape of the global therapeutic plasma exchange market. Key players operating in the global therapeutic plasma exchange market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global therapeutic plasma exchange market profiled in this report.

Key Questions Answered in Global therapeutic plasma exchange Market Report
• What is the sales/revenue generated by therapeutic plasma exchange across all regions during the forecast period?
• What are the opportunities in the global therapeutic plasma exchange market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Therapeutic Plasma Exchange Market – Research Objectives and Research Approach
The comprehensive report on the global therapeutic plasma exchange market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global therapeutic plasma exchange market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global therapeutic plasma exchange market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Therapeutic Plasma Exchange Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Therapeutic Plasma Exchange Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Indication, 2023–2031
6.3.1. Neurological Disorders
6.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
6.3.1.2. Myasthenia Gravis
6.3.1.3. Multiple Sclerosis
6.3.1.4. Neuromyelitis Optica
6.3.1.5. Guillain-Barre Syndrome
6.3.2. Renal Disorders
6.3.2.1. Post-renal Transplant Rejection
6.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
6.3.2.3. Wegener’s Granulomatosis
6.3.3. Hematology Disorders
6.3.3.1. Thrombotic Thrombocytopenic Purpura
6.3.3.2. Hemolytic Uremic Syndrome
6.3.3.3. Cryoglobulinemia
6.3.3.4. Multiple Myeloma
6.3.3.5. Metabolic Disorders
6.3.3.6. Homozygous Familial Hypercholesterolemia
6.3.3.7. Fulminant Wilson’s Disease
6.3.4. Others
6.4. Market Attractiveness Analysis, by Disease Indication
7. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023–2031
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness Analysis, by End-user
8. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Therapeutic Plasma Exchange Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Disease Indication, 2023–2031
9.3.1. Neurological Disorders
9.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
9.3.1.2. Myasthenia Gravis
9.3.1.3. Multiple Sclerosis
9.3.1.4. Neuromyelitis Optica
9.3.1.5. Guillain-Barre Syndrome
9.3.2. Renal Disorders
9.3.2.1. Post-renal Transplant Rejection
9.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
9.3.2.3. Wegener’s Granulomatosis
9.3.3. Hematology Disorders
9.3.3.1. Thrombotic Thrombocytopenic Purpura
9.3.3.2. Hemolytic Uremic Syndrome
9.3.3.3. Cryoglobulinemia
9.3.3.4. Multiple Myeloma
9.3.3.5. Metabolic Disorders
9.3.3.6. Homozygous Familial Hypercholesterolemia
9.3.3.7. Fulminant Wilson’s Disease
9.3.4. Others
9.4. Market Value Forecast, by End-user, 2023–2031
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Ambulatory Surgical Centers
9.5. Market Value Forecast, by Country, 2023–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Disease Indication
9.6.2. By End-user
9.6.3. By Country
10. Europe Therapeutic Plasma Exchange Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Indication, 2023–2031
10.3.1. Neurological Disorders
10.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
10.3.1.2. Myasthenia Gravis
10.3.1.3. Multiple Sclerosis
10.3.1.4. Neuromyelitis Optica
10.3.1.5. Guillain-Barre Syndrome
10.3.2. Renal Disorders
10.3.2.1. Post-renal Transplant Rejection
10.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
10.3.2.3. Wegener’s Granulomatosis
10.3.3. Hematology Disorders
10.3.3.1. Thrombotic Thrombocytopenic Purpura
10.3.3.2. Hemolytic Uremic Syndrome
10.3.3.3. Cryoglobulinemia
10.3.3.4. Multiple Myeloma
10.3.3.5. Metabolic Disorders
10.3.3.6. Homozygous Familial Hypercholesterolemia
10.3.3.7. Fulminant Wilson’s Disease
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Ambulatory Surgical Centers
10.4.4. Others
10.5. Market Value Forecast, by Country/Sub-region, 2023–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Disease Indication
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Therapeutic Plasma Exchange Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Indication, 2023–2031
11.3.1. Neurological Disorders
11.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
11.3.1.2. Myasthenia Gravis
11.3.1.3. Multiple Sclerosis
11.3.1.4. Neuromyelitis Optica
11.3.1.5. Guillain-Barre Syndrome
11.3.2. Renal Disorders
11.3.2.1. Post-renal Transplant Rejection
11.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
11.3.2.3. Wegener’s Granulomatosis
11.3.3. Hematology Disorders
11.3.3.1. Thrombotic Thrombocytopenic Purpura
11.3.3.2. Hemolytic Uremic Syndrome
11.3.3.3. Cryoglobulinemia
11.3.3.4. Multiple Myeloma
11.3.3.5. Metabolic Disorders
11.3.3.6. Homozygous Familial Hypercholesterolemia
11.3.3.7. Fulminant Wilson’s Disease
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Ambulatory Surgical Centers
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Disease Indication
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Therapeutic Plasma Exchange Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Indication, 2023–2031
12.3.1. Neurological Disorders
12.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
12.3.1.2. Myasthenia Gravis
12.3.1.3. Multiple Sclerosis
12.3.1.4. Neuromyelitis Optica
12.3.1.5. Guillain-Barre Syndrome
12.3.2. Renal Disorders
12.3.2.1. Post-renal Transplant Rejection
12.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
12.3.2.3. Wegener’s Granulomatosis
12.3.3. Hematology Disorders
12.3.3.1. Thrombotic Thrombocytopenic Purpura
12.3.3.2. Hemolytic Uremic Syndrome
12.3.3.3. Cryoglobulinemia
12.3.3.4. Multiple Myeloma
12.3.3.5. Metabolic Disorders
12.3.3.6. Homozygous Familial Hypercholesterolemia
12.3.3.7. Fulminant Wilson’s Disease
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Ambulatory Surgical Centers
12.4.4. Others
12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Disease Indication
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Therapeutic Plasma Exchange Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Indication, 2023–2031
13.3.1. Neurological Disorders
13.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
13.3.1.2. Myasthenia Gravis
13.3.1.3. Multiple Sclerosis
13.3.1.4. Neuromyelitis Optica
13.3.1.5. Guillain-Barre Syndrome
13.3.2. Renal Disorders
13.3.2.1. Post-renal Transplant Rejection
13.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
13.3.2.3. Wegener’s Granulomatosis
13.3.3. Hematology Disorders
13.3.3.1. Thrombotic Thrombocytopenic Purpura
13.3.3.2. Hemolytic Uremic Syndrome
13.3.3.3. Cryoglobulinemia
13.3.3.4. Multiple Myeloma
13.3.3.5. Metabolic Disorders
13.3.3.6. Homozygous Familial Hypercholesterolemia
13.3.3.7. Fulminant Wilson’s Disease
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Ambulatory Surgical Centers
13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Disease Indication
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Asahi Kasei Corporation
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Baxter International, Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Terumo Corporation
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. B. Braun SE
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Fresenius Kabi AG
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. SB-Kawasumi Laboratories, Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Haemonetics Corporation
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Cerus Corporation
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Charles River Laboratories
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Medica S.p.A.
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview